Viewing Study NCT04464850


Ignite Creation Date: 2025-12-24 @ 5:08 PM
Ignite Modification Date: 2025-12-30 @ 9:12 AM
Study NCT ID: NCT04464850
Status: UNKNOWN
Last Update Posted: 2020-08-11
First Post: 2020-07-06
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Intravenous Versus Oral Iron Therapy in Hemodialysis Patients
Sponsor: Chiang Mai University
Organization:

Study Overview

Official Title: Effects Intravenous Iron and Oral Iron Therapy on Erythropoietin Dose in Maintenance Hemodialysis Patients: An Open-label, Randomized, Controlled Study
Status: UNKNOWN
Status Verified Date: 2020-08
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: IVO-IRON
Brief Summary: This study is aim to compare the efficacy of intravenous versus oral iron therapy regarding the hemoglobin levels, iron status and erythropoietin dosage in maintenance hemodialysis patients
Detailed Description: Run-in phase: All eligible patients will enter run-in phase for 2 weeks. In this phase, all oral therapy that patients received before enrolment into the study will be discontinued.

Masking: Opened label

Allocation: Block of four randomization into 2 treatment arms: intravenous iron and oral iron

Safety criteria: Study participants who meet the following criteria will be discontinued from the study. All patients data will be analyzed according to intention-to-treat principles.

* Hemoglobin levels \< 6.0 g/dl
* Packed red cells transfusion is required
* Serum ferritin \>1,000 md/dl

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: